🔗 Share this article

Given that the United States proceeds with historic changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccines in the pandemic and has zeroed in on potential deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Program

Public health authorities had intended to unveil major revisions to the pediatric vaccination calendar recently, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the global community with no evidence for improved outcomes. The planned update has been pushed back until the coming year.

Rather than Vinay Prasad, Dr. Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for ending specific pediatric shot schedules in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious background in medication creation, oversight or administrative roles, which has been standard for former heads of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “grasp legal statutes and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran the center have had.”

This division has an immense range of responsibilities at the agency, she pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There is also a biologic copycat branch, OTC medication office and more, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a major management element to the position, which supervises in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” she added.

Response and Contentious Programs

In response to questions about Høeg’s qualifications and whether this selection represents increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “questions are based on incorrect premises”.

“Her resume matches the functions of her position,” the representative stated, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious one-day therapy clearance system that apparently troubled her predecessors. “By what process are these drugs being picked for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of pharmaceuticals, except for vaccines.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if problematic, history, Howard observe. She released a research paper using unverified volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the current administration encompassed revising guidelines for novel immunizations and halting “unnecessary” vaccines, she remarked following the vote on a online show. At the FDA, Høeg has allegedly suggested excluding young men from receiving Covid vaccinations.

“She is an thorough true believer who starts off with her beliefs and tailors the evidence to fit the data in a very disingenuous, untruthful way,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|